Skip to main content

REVIEW article

Front. Immunol.

Sec. Microbial Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1570233

This article is part of the Research Topic Host-Microbiota Immuno-Interactions for Personalized Microbial Therapeutics View all 5 articles

Therapeutic Targeting of the Host-Microbiota-Immune axis: Implications for Precision Health

Provisionally accepted
Asiya Nazir Asiya Nazir 1*Fathima Hasnain Nadeem Hussain Fathima Hasnain Nadeem Hussain 1Tuahir Hassan Nadeem Hussain Tuahir Hassan Nadeem Hussain 2Rania Al Dweik Rania Al Dweik 1Afsheen Raza Afsheen Raza 1
  • 1 Abu Dhabi University, Abu Dhabi, United Arab Emirates
  • 2 Center for Biotechnology, Khalifa University, Abu Dhabi, Abu Dhabi, United Arab Emirates

The final, formatted version of the article will be published soon.

    The human body functions as a complex ecosystem, hosting trillions of microbes that collectively form the microbiome, pivotal in immune system regulation. The host-microbe immunological axis maintains homeostasis and influences key physiological processes, including metabolism, epithelial integrity, and neural function. Recent advancements in microbiome-based therapeutics, including probiotics, prebiotics and fecal microbiota transplantation, offer promising strategies for immune modulation. Microbial therapies leveraging microbial metabolites and engineered bacterial consortia are emerging as novel therapeutic strategies. However, significant challenges remain, including individual microbiome variability, the complexity of host-microbe interactions, and the need for precise mechanistic insights. This review comprehensively examines the host microbiota immunological interactions, elucidating its mechanisms, therapeutic potential, and the future directions of microbiome-based immunomodulation in human health. It will also critically evaluate challenges, limitations, and future directions for microbiome-based precision medicine.

    Keywords: Gut Microbiota, Microbiota-immune interactions, microbiota therapeutics, Probiotics, fecal microbiota transplantation, Precision medicine and microbiome, Microbial dysbiosis

    Received: 03 Feb 2025; Accepted: 24 Mar 2025.

    Copyright: © 2025 Nazir, Hussain, Nadeem Hussain, Al Dweik and Raza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Asiya Nazir, Abu Dhabi University, Abu Dhabi, United Arab Emirates

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more